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Sir, I read with interest the study by Nimbalkar et al. on the tuberculin purified protein derivative (PPD) immunotherapy in the treatment of viral warts. [1] The authors found that such treatment modality was safe, simple to perform, not very painful, inexpensive with minimal side effects, effective with good cure rate in the treatment of single and multiple warts, equally effective at injected and warts at distant site, and prevents recurrence of warts with completely clearance. [1] I presume that the implication of that treatment modality in the clinical field should be taken cautiously. This is based on the following point. It is obvious that tuberculosis (TB) is a major public health problem in India which accounts for nearly one-fifth of the global TB burden. Although India has been gaining success in eliminating TB, the disease still kills 1000 people daily. [2] Latent TB is serious as it serves as a potential reservoir for future active TB. Thus, the identification and treatment of latent TB in those at the highest risk for progression is an essential component of TB control program worldwide. It is well-known that tuberculin skin test (TST) and interferon-gamma release assay (IGRA) are two essential tests incorporated in the diagnostic algorithm of TB, particularly the latent TB. Several guidelines have recommended a two-step testing procedure, notably TST followed by IGRA for the diagnosis of latent TB. Great concerns have been raised on the correlation between prior TST exposure and subsequent IGRA. The TST usually involves multiple antigens of tuberculin PPD, including the antigens used in IGRA. Exposure to these antigens by means of a TST might elicit an immune response that could lead to the false-positive result in a subsequent IGRA, thus limiting the validity of IGRA in individuals in whom these tests are sequentially done. Reviewing the literature on the effect of a previous TST on the result of the subsequent IGRA revealed generally distressing results. For example, a systematic review on that issue has shown that although the effect of TST on IGRA results was likely to be inconsequential in IGRA-positive participants and in IGRA-negative participants, the interpretation of results might be confounded by a preceding TST if administered more than 3 days before an IGRA. [3] A set of Italian researchers have shown that TST did not influence the outcome of subsequent IGRA testing in individuals with negative TST results, but it could boost the interferon-gamma response in participants sensitized to TB antigens and not detected by IGRA. [4] However, a set of Korean researchers obviously pointed out that the agreement between the results of the TST and the IGRA was low, and interferon-gamma level could be influenced by the TST, in the TST-positive population, when a follow-up IGRA was performed 2-4 weeks later. [5] I, therefore, presume that inquiry about antecedent tuberculin PPD exposure for the treatment of viral warts should be taken into consideration during interpreting the results of IGRA in individuals with suspected TB in India.
Sir,
A 45-year-old Indian male presented with multiple raised skin lesions on his face since past 5-6 years. Lesions were asymptomatic, without any seasonal variation and had progressively increased in number. The patient was in good health and had no other symptoms. Family history was not significant. On cutaneous examination, his facial skin was greasy and he had numerous, skin-colored, firm, umbilicated papules on the face, measuring 2-5 mm, distributed mainly in the centrofacial region, i.e., nose, nasolabial folds, and perinasal area, but a few other lesions were also present on the cheeks and forehead [Figures 1a and 2a ]. Rest of the cutaneous examination was normal. A skin biopsy from one of the papules showed an intact epidermis, normal lobules of mature sebaceous glands and gland duct in the dermis [ Figure 3 ]. These findings were consistent with a diagnosis of sebaceous hyperplasia. We planned to start the patient on oral isotretinoin, in a dose of 0.5 mg/kg along with sessions of 30% salicylic acid chemical peeling, once every two weeks; the patient was followed every two weeks. This treatment plan resulted in complete clearing of lesions within 6 weeks [ Figures 1b and 2b] , with a total cumulative dose of 21mg/kg of isotretinoin. At this point of clinical cure, isotretinoin was discontinued and we were able to maintain the patient on just monthly salicylic acid chemical peels. The patient showed no sign of recurrence of SGH at 6 months follow up.
Sebaceous gland hyperplasia is a benign condition and presents primarily on the face as asymptomatic, skin-colored or yellowish, umbilicated papules. Traditional methods of treatment such as cryosurgery, electrodesiccation, curettage, shave excision, and topical trichloroacetic acid/ bichloroacetic acid involve destruction of entire gland but can lead to sequelae such as scarring and discoloration. Therefore, depending on the number of lesions and the 
